Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Bullboard - Stock Discussion Forum HAVN Life Sciences Inc C.HAVN

Alternate Symbol(s):  HAVLF

HAVN Life Sciences Inc. is a Canada-based biotechnology company. The Company is engaged in the scientific research and development of psychopharmacological and natural health care products. It is focused on standardizing extraction of psychoactive compounds, the development of natural health products, and developing mental health treatments to support brain health and enhance the capabilities... see more

CSE:HAVN - Post Discussion

HAVN Life Sciences Inc > HAVN News Release
View:
Post by Idvhmz123 on Feb 18, 2021 8:33am

HAVN News Release

Havn Life Announces Changes to Board Composition and Departure of Ms. Rasode February 17, 2021, 8:00 am VANCOUVER, BC / ACCESSWIRE / February 17, 2021 / Havn Life Sciences Inc. (CSE:HAVN)(OTC PINK:HAVLF)(FSE:5NP) (the "Company" or "Havn Life"), announces the departure of Ms. Barinder Rasode as President and as a director of the Company, effective immediately. The Company also announces that its Chief Executive Officer, Mr. Tim Moore, has been appointed as a director of the Company. Ms. Rasode commented, "We created Havn Life to benefit human health and harness the medicine found in nature. I am so pleased with how far we have come in such a short time. It was always my intention to leave once the right team was in place and the Company well-positioned for success. That time has come, and I leave with confidence and excitement about the Company's future." Mr. Vic Neufeld, Chairman of the Board of Havn Life, commented, "I'd like to thank Barinder for her vision in co-founding the Company and for her contributions toward realizing that vision, and I look forward to her continued support as a shareholder. The Company is extremely fortunate to have in Tim Moore a CEO who has a deep understanding of the biotechnology industry and who has demonstrated time and again the ability to achieve operational milestones while keeping key stakeholders and the wider investment community thoroughly engaged. It's a pleasure to welcome Tim to the Board. We are very excited to strengthen his leadership of the Company and for the future of Havn Life." Mr. Tim Moore commented, "I welcome the opportunity to join the Havn Life Board. We have laid the foundation for continued good governance, with four of five Board members remaining independent of management, and I look forward to adding value in this new capacity as we pursue execution of our business plan." On Behalf of The Board of Directors
Comment by up2005 on Feb 18, 2021 7:12pm
Is this a concern for the company. As a co-founder of HAVN does the departure of Ms. Barinder Rasode send a negative message. Is she going to start up another related company? Might have timed my entry wrong. Time will tell, so much more research is needed for these psycho-pharmacological drugs. Have to sit tight for 3-4 months and reevaluate.
The Market Update
{{currentVideo.title}} {{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >

At the Bell logo
A daily snapshot of everything
from market open to close.

{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}{{currentVideo.intervieweeTitle}}
< Previous
Next >
Dealroom for high-potential pre-IPO opportunities